DRS | Jotup

Quantum Computing Inc. Congratulates Achievement as its Engineers Receive Prestigious Edison Patent Award for Groundbreaking Quantum Cybersecurity Invention

Retrieved on:

Thursday, January 18, 2024

Privacy, Physics, OCI, Photon, Computer security, DRS, Government, Data mining, Environment, Paramount, Internet, Patent

This recognition underscores their exceptional work in addressing cybersecurity threats and developing innovative solutions, including a revolutionary method of quantum authentication and private-data computing that can process and verify information without sharing that information.

Key Points:

This recognition underscores their exceptional work in addressing cybersecurity threats and developing innovative solutions, including a revolutionary method of quantum authentication and private-data computing that can process and verify information without sharing that information.
The Edison Patent Award, a symbol of innovation and excellence, is a testament to the commitment, expertise, and innovation demonstrated by Dr. Yuping Huang, OCi's Chief Quantum Officer and Dr. Lac Thi Thanh Nguyen, the Quantum Technology Lead for QCi's Cybersecurity platform.
Their critical work has significantly advanced Quantum Computing Inc's mission to harness the power of quantum technologies for real-world applications.
The patent underlying the award represents a milestone in the field of quantum information networks, a critical domain in the ongoing battle against cybersecurity threats facing industry, government, and individuals.

Ratio Therapeutics Announces $50M Series B Financing to Advance Targeted Radiotherapies for Cancer Treatment

Retrieved on:

Wednesday, January 17, 2024

Bristol Myers Squibb, DRS, Cancer, Radiopharmaceutical, Patient, Cornell University, FAP, Pharmaceutical industry

BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, today announces the close of its $50M Series B financing, bringing the total raised to date to over $90 million. The latest round witnessed continued participation from Series A leads Schusterman and Duquesne and welcomed among others PagsGroup, Bristol Myers Squibb and the Center for Technology Licensing at Cornell University.

Key Points:

BOSTON, Jan. 17, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the treatment and monitoring of cancers, today announces the close of its $50M Series B financing, bringing the total raised to date to over $90 million.
This financing will expand the applications of the company's proprietary technology platforms, Trillium™ and Macropa™, to develop novel best in class fit-for-purpose radiopharmaceuticals.
Additionally, the funding will drive the clinical development of the company's fibroblast activation protein-alpha (FAP) targeted radiopharmaceutical therapeutic.
Babich and Hoppin standing as pioneers in the radiopharmaceutical field, we believe they are very well positioned to advance novel radiopharmaceutical cancer treatments and diagnostics into the clinic."

Glaucoma Innovations to be Presented at 13th Annual New Horizons Forum in San Francisco

Retrieved on:

Tuesday, January 16, 2024

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire/ -- Glaucoma Research Foundation (GRF) will host the 13th Annual Glaucoma 360 New Horizons Forum on February 9th at San Francisco's historic Westin St. Francis Hotel.

Key Points:

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire/ -- Glaucoma Research Foundation (GRF) will host the 13th Annual Glaucoma 360 New Horizons Forum on February 9th at San Francisco's historic Westin St. Francis Hotel.
Dr. Ianchulev's keynote lecture "The Innovation Journey of an iDoctor" will shed light on recent and on-the-horizon advances in glaucoma care.
The complete program agenda can be viewed on the New Horizons Forum website .
New Horizons Forum is the centerpiece of Glaucoma 360 , GRF's signature three-day series of events planned for February 8 to 10, 2024.

Cullgen Announces Additions to Board of Directors and Scientific Advisory Board

Retrieved on:

Tuesday, January 16, 2024

Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced the addition of Xiaogang Pan, PhD to its Board of Directors, and Ian Storer, PhD to its Scientific Advisory Board.

Key Points:

Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™ platform of targeted protein degradation technology, today announced the addition of Xiaogang Pan, PhD to its Board of Directors, and Ian Storer, PhD to its Scientific Advisory Board.
Pan Xiaogang, currently Managing Director of AstraZeneca-CICC Fund and Business Development in AstraZeneca China, leads the investment activities in innovative medicine.
Xiaogang has nearly 20 years of combined experiences in research, business development and investment.
Pan and Storer join Cullgen in these important advisory roles.

THE AMERICAN ACADEMY OF COSMETIC SURGERY (AACS) MARKS ITS 40th ANNIVERSARY WITH A COMPREHENSIVE SCIENTIFIC MEETING, PRE-MEETING WORKSHOP, AND DIVERSE OFFERINGS

Retrieved on:

Tuesday, January 16, 2024

CHICAGO, Jan. 16, 2024 /PRNewswire/ -- The American Academy of Cosmetic Surgery (AACS), the world's largest multi-specialty home for physicians dedicated to cosmetic surgery and aesthetic medicine, will present its 40th Annual Scientific Meeting (ASM) on February 22-24, 2024, with an optional pre-meeting workshop on Ultrasound for Safe Brazilian Butt Lift Surgery and More, on Wednesday, February 21.

Key Points:

In celebration of the AACS' 40th Annual Scientific Meeting, and the 40-year anniversary of the formation of the Academy and its official publication, The American Journal of Cosmetic Surgery, the meeting includes a comprehensive scientific program, as well as an array of advocacy, enrichment, networking and 40th anniversary celebratory activities.
Offering 41 educational sessions , the 2024 AACS ASM features foremost experts spanning diverse background specialties, such as dermatology, otolaryngology, general surgery, oral, and maxillofacial surgery, ophthalmology, and plastic and reconstructive surgery.
J. Kevin Duplechain, MD, FAACS, cosmetic surgeon and Immediate Past-President of the AACS and Cosmetic Surgery Foundation, will deliver the prestigious Webster Lecture on Friday, February 23.
Cosmetic surgery practitioners may register here for the 2024 AACS ASM.

Photonics Technologies to Expedite Environmental Analysis

Retrieved on:

Friday, January 12, 2024

Thought, Research, Photonics, COP28, Vanderbilt University, Health, Knowledge, DRS, Gas, Wang, Plastic, Environment, Selection Committee, Conference, Greenhouse, USD, Soil, Infant

WASHINGTON, Jan. 12, 2024 /PRNewswire/ -- The Optica Foundation today released details on the environmental research funded by the 2023 Optica Foundation Challenge. Researchers Justus Ndukaife, Vanderbilt University, USA, and Yicheng Wang, Ruhr-Universität-Bochum/Photonics and Ultrafast Laser Science (PULS), Germany, both are working to create light-based solutions to sense, measure and address environmental toxins in the form of nanoplastics and greenhouse gases.

Key Points:

WASHINGTON, Jan. 12, 2024 /PRNewswire/ -- The Optica Foundation today released details on the environmental research funded by the 2023 Optica Foundation Challenge .
Ndukaife and Wang have proposed photonics solutions to detect environmental toxins.
Ndukaife and Wang have proposed innovative photonics solutions to more efficiently and rapidly detect environmental toxins so they can be mitigated and avoided."
In fact, 79% of all plastic that has ever been made still sits in landfills or the natural environment.

OneOncology Partners with Huntsville's Clearview Cancer Institute

Retrieved on:

Friday, January 12, 2024

Physician, PET/CT, DRS, Partnership, Patient, MRI, CCI, Hospital, Nursing

NASHVILLE, Tenn. and HUNTSVILLE, Ala., Jan. 12, 2024 /PRNewswire/ -- Clearview Cancer Institute and OneOncology, the fastest-growing national platform for independent oncology practices, announced a finalized partnership to enhance the delivery of cancer services to Alabama communities.

Key Points:

NASHVILLE, Tenn. and HUNTSVILLE, Ala., Jan. 12, 2024 /PRNewswire/ -- Clearview Cancer Institute and OneOncology, the fastest-growing national platform for independent oncology practices, announced a finalized partnership to enhance the delivery of cancer services to Alabama communities.
Clearview Cancer Institute is 1 of the 5 largest community oncology practices nationally and the largest in Alabama.
Clearview Cancer Institute is one of the five largest community oncology practices nationally and the largest in Alabama.
Clearview Cancer Institute has been caring for the lives of Alabamians for over 30 years, offering patients high quality, personalized healthcare close to their own home.

SKYTALE GROUP SERVES AS EXCLUSIVE FINANCIAL ADVISOR TO THE BENGTSON CENTER FOR AESTHETICS AND PLASTIC SURGERY AND SYMMETRY MEDSPA

Retrieved on:

Monday, January 8, 2024

Associate, Partnership, DRS, Symmetry, Growth, UAA, Aesthetics, Varsity, Pleasure, Senior

BCAPS, located in Grand Rapids Michigan, is led by two board-certified plastic surgeons, Drs.

Key Points:

BCAPS, located in Grand Rapids Michigan, is led by two board-certified plastic surgeons, Drs.
The Company is one of the leading medical aesthetics and plastic surgery practices in the nation offering a comprehensive suite of plastic surgery, injectables, and aesthetic services.
"This transaction quite simply, would have been impossible to navigate and complete without Skytale," states Dr. Bengtson.
Skytale Managing Director, Ben Hernandez; Senior Vice President, Tedd Van Gorden; Associate, James Wimpress; Senior Analyst, Christian Guy; and Analyst, Tommy Steis represented BCAPS in the partnership process.

RIVERMARK MEDICAL ANNOUNCES COMPLETION OF EXPANDED INDICATION STUDY FOR THE FLOSTENT™ SYSTEM

Retrieved on:

Monday, January 8, 2024

Urine, Entrepreneurship, Urinary retention, Risk, Rivermark of Santa Clara, Advocate Aurora Health, Urology, DRS, Trial of the century, Prostate, FIH, Patient, Diagnosis, BPH

MILWAUKEE, Jan. 8, 2024 /PRNewswire/ -- Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the successful completion of its RAPID-UR study, an extended indication study that evaluated the use of the Company's FloStent System in patients suffering urinary retention due to BPH. The pilot study included 11 patients, and procedures were performed by Drs. Ingrid Perscky and Ruben Urena at the Pacifica Salud Costa del Este Hospital in Panama City, Panama.

Key Points:

Ingrid Perscky and Ruben Urena at the Pacifica Salud Costa del Este Hospital in Panama City, Panama.
Urinary retention (UR) refers to a patient's inability to pass urine, often requiring placement of a temporary indwelling catheter for relief.
We are confident this expanded application of the FloStent System will address this critical unmet need."
Clinical data from the RAPID-I FIH study, along with results from the expanded indication study, RAPID-UR, will be presented at upcoming Urology congresses.

Evaxion Announces Plan to Implement ADS Ratio Change

Retrieved on:

Monday, January 8, 2024

Depository Trust Company, ADS, Tax, Bank, Sale, DKK, Effective date, Ratio, DTC, Depositary, BNY Mellon, American depositary receipt, DRS, Security (finance)

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”).

Key Points:

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS Ratio”), from the current one (1) ADS representing one (1) ordinary share to a new ADS Ratio of one (1) ADS representing ten (10) ordinary shares (the “ADS Ratio Change”).
The ADS Ratio Change is expected to become effective on or about January 22, 2024, U.S. Eastern Time (the “Effective Date”).
For the Company’s ADS holders, the change in the ADS Ratio will have the same effect as a one-for-ten reverse ADS split and is intended to further support the liquidity in the Company’s ADSs and to enable the Company to regain compliance with the Nasdaq minimum bid price requirement.
As a result of the ADS Ratio Change, the ADS trading price is expected to increase proportionally, although the Company can give no assurance that the ADS trading price after the ADS Ratio Change will be proportionally equal to or greater than the previous ADS trading price prior to the change or that the Ratio Change will have any effect on the liquidity in the Company’s ADSs.